Investor Update
Basel, 2 November 2007
Pharmasset
Presents
R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C; -Nucleoside polymerase
inhibitor demonstrates >99% mean decrease in HCV RNA with no serious adverse events
Dear
Investor,
Please find attached a Pharmasset news release sent out
today.